Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zyvox is exceptional, PhRMA says

Executive Summary

The Pharmaceutical Research and Manufacturers of America offers its first Clinical Trial Exceptional Service Award to Donald Batts (Michigan State University), Sharon Nachman (Stony Brook University) and Maryam Imam, an 11 year-old volunteer patient on March 14. The two researchers helped make advances in clinical trials that led to the development of Pfizer's Zyvox (linezolid) for treatment of drug-resistant bacterial infections...

You may also be interested in...



Pfizer Halts Pursuit Of Zyvox Indication Based On Mortality Signal

Pfizer will not pursue an indication for catheter-related infections for Zyvox (linezolid) after data from a Phase III trial indicated an increased risk of death among patients with the infections treated with the oxazolidinone antibiotic

Source: 3 Former Obama US CMS Officials Being Considered To Lead Biden’s Medicare Agency

The three names under consideration also have a history of focusing on helping underprivileged communities get access to health care.

Hikma Opens Discussions To Acquire GSK OTC, Rx Businesses In Egypt, Tunisia

With operations in the MENA region already tracking to $700m in revenues for 2020, Hikma is looking to grow the business further after beginning negotiations with GSK to buy certain of the originator’s businesses in Egypt and Tunisia.

UsernamePublicRestriction

Register

OM004634

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel